section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Availability

Route/Dosage

US Brand Names

Takhzyro

Action

  • Acts as a selective, reversible inhibitor of kallikrein, thereby inhibiting its action in initiating bradykinin production, part of the cascade of events in hereditary angioedema.
Therapeutic effects:
  • Reduction in number of hereditary angioedema attacks.

Classifications

Therapeutic Classification: antiangioedema agents

Pharmacologic Classification: kallikrein inhibitors, monoclonal antibodies

Pharmacokinetics

Absorption: Well absorbed following SUBQ administration.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: 14–15 days.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
SUBQunknown4–5 daysunknown



Patient/Family Teaching

Pronunciation

LAN-a-DEL-ue-mab